Feature | July 02, 2014 | Melinda Taschetta-Millane

Trends from SNMMI 2014

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently held its annual meeting in St. Louis. It provided an in-depth review of molecular imaging technologies, clinical applications, and translational and advanced research topics for molecular imaging professionals — nuclear medicine physicians, scientists, radiologists, cardiologists, pharmacists, technologists, researchers, and others involved and interested in nuclear medicine and molecular imaging and therapy.

On the show floor, several vendors introduced new PET/CT systems for the market. 

Among them was Philips’ Vereos, which is the first on the market to offer digital PET detectors, and offers greater image clarity over traditional analog photomultipliers. 

Toshiba announced the release of its Celesteion system. It currently is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA), and combines high-performance PET and CT for all radiation and oncology imaging needs, including tumor detection, treatment evaluation and CT simulation.

In addition, GE Healthcare introduced its Discovery IQ PET/CT system. It enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the FDA and not available for sale in the United States. 

You can learn more about the trends and technology showcased at SNMMI 2014 by viewing the videos Editor’s Choice of Most Innovative Technology at SNMMI 2014” and “SNMMI: Trends and New Technology in Nuclear Imaging.” 

Several interesting studies came out of the show, as well, and covered a vast spectrum of topics, including:

• Antibody-based molecular imaging agent hones in on newly targeted cell receptor that 

hints at more aggressive breast cancers and potential therapy;

• Molecular neuroimaging shows a strong association between a sleep disorder and the development of progressive brain diseases such as Parkinson’s;

• Study finds the newest hybrid cardiac molecular imaging system highly effective for the detection of coronary arterial disease;

• Molecular imaging study suggests late-life depression and beta-amyloid plaque in the brain could tip-off hastened development of deadly dementia;

• Researchers can now use radioluminescence to examine the characteristics of single, unconnected cells, and the result is a fascinating picture of diversity among cells previously assumed to behave the same; and

• Wide range of molecular imaging modalities is at researchers’ fingertips with a hybrid device dedicated for early-stage clinical trials.

As always, you can read more about these innovative studies, as well as other industry news, at www.itnonline.com

Related Content

Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Overlay Init